1. Home
  2. SCNI vs VTAK Comparison

SCNI vs VTAK Comparison

Compare SCNI & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCNI
  • VTAK
  • Stock Information
  • Founded
  • SCNI 2003
  • VTAK 2002
  • Country
  • SCNI Israel
  • VTAK United States
  • Employees
  • SCNI N/A
  • VTAK N/A
  • Industry
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • VTAK Medical/Dental Instruments
  • Sector
  • SCNI Health Care
  • VTAK Health Care
  • Exchange
  • SCNI Nasdaq
  • VTAK Nasdaq
  • Market Cap
  • SCNI 4.6M
  • VTAK 4.1M
  • IPO Year
  • SCNI N/A
  • VTAK 2018
  • Fundamental
  • Price
  • SCNI $1.45
  • VTAK $2.46
  • Analyst Decision
  • SCNI
  • VTAK
  • Analyst Count
  • SCNI 0
  • VTAK 0
  • Target Price
  • SCNI N/A
  • VTAK N/A
  • AVG Volume (30 Days)
  • SCNI 95.7K
  • VTAK 395.8K
  • Earning Date
  • SCNI 11-21-2025
  • VTAK 11-14-2025
  • Dividend Yield
  • SCNI N/A
  • VTAK N/A
  • EPS Growth
  • SCNI N/A
  • VTAK N/A
  • EPS
  • SCNI 0.26
  • VTAK N/A
  • Revenue
  • SCNI $1,147,000.00
  • VTAK $600,000.00
  • Revenue This Year
  • SCNI N/A
  • VTAK $822.86
  • Revenue Next Year
  • SCNI N/A
  • VTAK $168.42
  • P/E Ratio
  • SCNI $5.50
  • VTAK N/A
  • Revenue Growth
  • SCNI 303.87
  • VTAK 37.62
  • 52 Week Low
  • SCNI $1.20
  • VTAK $2.20
  • 52 Week High
  • SCNI $6.18
  • VTAK $15.68
  • Technical
  • Relative Strength Index (RSI)
  • SCNI 50.03
  • VTAK 43.85
  • Support Level
  • SCNI $1.43
  • VTAK $2.53
  • Resistance Level
  • SCNI $1.52
  • VTAK $2.69
  • Average True Range (ATR)
  • SCNI 0.09
  • VTAK 0.19
  • MACD
  • SCNI 0.01
  • VTAK -0.04
  • Stochastic Oscillator
  • SCNI 53.06
  • VTAK 2.78

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Share on Social Networks: